Joel Schaedler is a seasoned healthcare executive with over twenty-four years of experience within the pharmaceutical, biotech, and specialty therapeutic arenas. His professional experience has been within the public and private sectors. He has worked in various leadership roles with three pharmaceutical and biotech organizations and was integral in the launch of seven FDA approved products. On the private side, he has been an active leader and principle of six, private specialty therapeutic organizations.
Joel Schaedler started his healthcare career with Rhône Plaunc Rorer Pharmaceuticals. He held positions of increasing leadership responsibility across the asthma/allergy and oncology divisions of the organization. This included the launch of the market-leading solid tumor therapeutic Taxotere. Post RPR, he held a leadership position with the initial team that built-out the immunology division at Centocor. This division was a start-up division of Centocor that included the launch of the blockbuster biotechnology agent Remicade. Centocor was eventually sold to Johnson and Johnson, and Remicade remains a significant drug asset in the Johnson and Johnson portfolio of specialty therapeutics.
Joel ventured into the private space post-Centocor. He accepted the position of VP, New Business Development at the International Oncology Network (ION) and the International Physicians Network (IPN). These organizations were charged with developing a value-based model with key community based, specialty therapeutic practices across the United States. The specialties of focus were oncology, urology, rheumatology, nephrology, and dermatology. Both organizations were eventually acquired by AmerisourceBergen and are housed within the AmerisourceBergen specialty division.
Joel continued down the start-up route as he led the build-out of both BioniCare and Primus Pharmaceuticals. In these strategy facing, executive level positions, he helped both organizations develop a commercial strategy to launch into the pain and anti-inflammatory markets. This included the development of business and revenue plans that would advance the commercial platforms of both organizations’ foundational assets.
In 2005, Joel became a founder in P4 Healthcare. P4 Healthcare was a revenue cycle and clinical cycle management company that interfaced with community specialty practices to drive greater efficiencies and better patient outcomes.It was one of the largest community oncology networks and had a national presence within the commercial payer landscape. In his role, Joel led the strategic pillars of the organization and built the commercial team that performed to the revenue and operational targets. P4 Healthcare was sold to Cardinal Health in 2010.
Joel ventured back into the start-up specialty healthcare space in 2012 when he accepted an executive team position with Heron Therapeutics. Heron Therapeutics is commercially focused on the oncology space with the developmental asset Sustol for chemotherapy-induced nausea and vomiting. Joel was the lead for the strategic access priorities as Sustol was in the pre-commercial phase and nearing commercial launch.
Joel graduated with a Bachelor of Science from Kent State University. He continues his connectivity with the university via his strategic advisory role position.
